Vertex Pharmaceuticals Incorporated

By default your notes are visible only to you.

362.5

52-week range

507.9

447.54

Your model inputs

Required return / cost of capital

FCFF terminal growth rate

Your fair value & Margin of safety

To calculate fair value based on cost of capital and terminal growth assumptions above, please select free cash flow forecast.

Forecast:

Valuation

Free Cash Flow Yield

FCF Yield TTM = Trailing Twelve Months free cash flow per share / current market price per share

3.2 %

Dividend Yield TTM

Market cap $

$ 113,588

Price / Earnings TTM

P/E TTM = current market price per share / Trailing Twelve Months diluted earnings per share

26.5

Price / Book TTM

5.9

PEG TTM

Price/Earnings-to-Growth ratio = P/E TTM divided by most recent annual diluted earnings per share growth rate

Earnings growth and return

LTM

5YR

10YR

Total return (price & dividends)

0.1 %

114.5 %

395.2 %

Free cash flow per share growth

504 %

8.9 %

827.3 %

Earnings per share growth

836.5 %

48.9 %

763.2 %

Founded: 1,989

Employees: 6,100

Business Summary:Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Fair Value Reference Estimate